| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Novavax, Inc. (NASDAQ:NVAX) shares are trading higher Thursday. Here’s what you need to know.
What Happened: The company experienced a drop in short interest, with short percent of float falling 25.64% since the last report, now at 25.55%. Thursday’s trading volume is at 6.715 million shares traded at the time of writing compared to the 100-day average of 16.708 million. The stock is also trending across social media platforms like StockTwits.
What Else: Earlier this month, Novavax announced it filed for authorization with Health Canada for its updated 2024-2025 protein-based COVID-19 vaccine, NVX-CoV2705, for individuals aged 12 and older. If approved, it will be the only protein-based COVID-19 vaccine available in Canada.
Novavax has also filed with the U.S. FDA and EMA, aiming for global approval. The vaccine aligns with recommendations from major health authorities like NACI, U.S. FDA, EMA and WHO.
NVAX Price Action: Novavax’s share were up by 8.5% at $16.78 according to Benzinga Pro.
See Also:
Photo: Marco Verch from Flickr.
Posted In: NVAX
